Marijn E. Dekkers - Jun 10, 2022 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Director
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Jun 10, 2022
Transactions value $
$0
Form type
4
Date filed
6/13/2022, 09:17 PM
Previous filing
May 13, 2022
Next filing
Jun 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Award $0 +70.9K +3.34% $0.00 2.19M Jun 10, 2022 Direct F1
holding DNA Class A Common Stock 5.78M Jun 10, 2022 By Novalis LifeSciences Investments I, L.P. F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Stock Option Award $0 +109K $0.00 109K Jun 10, 2022 Class A Common Stock 109K $2.82 Direct F1, F3

Explanation of Responses:

Id Content
F1 The vesting date of the restricted stock units and stock options, and in the case of the stock options, the exercise date, will be the earlier of either June 10, 2023 or the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date.
F2 The reporting person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.
F3 In accordance with the Non-Employee Director Compensation Policy of the Issuer, the Black-Scholes value of the option award as of the grant date is $200,000.